Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2000

View Archived Issues

Ribozyme repurchases rights to Heptazyme; phase II trial to begin

Cellegy's Rx for sexual dysfunction in women completes phase I/II

Canadian approval sought by Avanir for docosanol cream

Myogen to use SBIR grant for cardiac hypertrophy drug discovery

Two dendritic/cancer cell fusion trials begun by Genzyme Molecular Oncology

Atrix/Elan joint venture for cancer pain therapy selects fentanyl as first development compound

AMG-073 normalizes total serum calcium in hyperparathyroidism

LY-510929: Ligand's new drug candidate for diabetes and obesity

Vardenafil's preclinical profile supports potential in ED; other PDE5 inhibitors in the pipeline

Prophylactic efficacy of FK-463 against P. carinii infection demonstrated in mice

ABT-773 shows promise as antimicrobial agent in bite wound infections

Natural compound improves hypertension

Novel marine antifungal products sought in MycoLogics collaboration

Wyeth-Ayerst presents new SERM with potentially improved therapeutic profile

Analgesic activity of S-19812 assessed in rodent models and reported at OARSI meeting

Potent and selective EP2 receptor agonist with bone anabolic effects presented at ASBMR

Central 5-HT2C receptor agonist exerts proerectile activity in two animal species

Neuroprotective adenosine receptor ligands emerge from Novo Nordisk SAR studies

New triazole antifungal in development for use in deep mycoses

Favorable in vitro profile reported at ICAAC for BCH-13520, a new anti-HIV candidate

Small-molecule inhibitor of MT1-MMP discovered at Parke-Davis

Novel series from Isis Innovation possesses antiprotozoal, antitumor and other activities

Lilly's new 5-ht1F receptor agonists and their use in migraine

Two series synthesized at Boehringer Ingelheim exert sodium channel blockade

Steroid vitronectin receptor ligands discovered during joint research program

AstraZeneca presents new tyrosine kinase inhibitors with immunomodulating activity

Benzenesulfonamide B2 antagonists synthesized at Fournier

NitroMed's newest NO- and/or NO2-containing proton pump inhibitors

Popular Stories

23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Today's news in brief
BioWorld
BioWorld briefs for June 18, 2025.
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 18, 2025.
EACR 2025: Immune rewiring in cancer orchestrates tumor microenvironment
BioWorld Science
Among the presentations included in the Top Abstracts category at the recently inaugurated Annual Congress of the European Association for Cancer Research (EACR)...